RPCEC00000095CompletedPhase 3
Efficacy and safety of mebendazole compared with secnidazole in the treatment of adult giardiasis: a randomised clinical trial
Central Military Hospital Carlos J. Finlay0 sites110 target enrollmentStarted: April 21, 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 110
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment
Eligibility Criteria
- Ages
- 18 years to one (—)
- Sex
- All
Inclusion Criteria
- •Informed-consent form signed. Patients with 18 years and older.
Exclusion Criteria
- •Patients who had previously received any antiparasitic drug within 1 month before entering the study. Have known about any hypersensitivity to any of the drugs in use. Have any immunodeficiency disease. Have any hepatic disease. Have any renal disease. Have any cardiovascular disease. Have any haematological disease. Have used other drugs joined to the drugs in use. Women were pregnant or lactation.
Investigators
Similar Trials
Completed
Not Applicable
Efficacy and safety of anti-worm drugs in schoolchildren in Zanzibar, TanzaniaSoil-transmitted helminthiasisInfections and InfestationsOther helminthiasesISRCTN08336605Swiss Tropical Institute (STI) (Switzerland)2,000
Completed
Not Applicable
Comparative efficacy of albendazole and mebendazole against hookworm infection in LaosISRCTN29126001Swiss National Science Foundation (Switzerland)190
Completed
Phase 3
Treatment of Giardiasis with Praziquantel or Mebendazolegiardiasis.Giardiasis [lambliasis]IRCT138708131431N1Shahrekord university of medical sciences600
Recruiting
Phase 3
Effect of Topical Metronidazole in treatment of chronic fissureChronic Anal Fissure.Chronic anal fissureK60.1IRCT20221102056377N1Shahid Beheshti University of Medical Sciences54
Recruiting
Not Applicable
Effects of Mebendazole to Lenvatinib (drug) in liver cancerCTRI/2020/06/026240Institute of Liver and Biliary Sciences